Blood thinner combo tested for leg artery disease

NCT ID NCT05009862

Completed Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This completed Phase 4 trial studied 60 people with peripheral artery disease (PAD) to see if adding low-dose rivaroxaban to aspirin improves blood vessel function and reduces clotting. Participants took either rivaroxaban plus aspirin or a placebo plus aspirin. The study measured changes in artery dilation and platelet activation using ultrasound and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban (a blood thinner) plus aspirin
What this could lead to: If successful, this could show that low-dose rivaroxaban plus aspirin improves blood vessel health and reduces clotting risk in people with peripheral artery disease.
What could go wrong: This is a small, completed study (60 participants) looking at lab markers, not major clinical outcomes like heart attacks or amputations. Results may not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL DISEASE

Contacts and locations

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.